Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBIT (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBIT for 10 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 40.22% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Dec 2025, up 146.56% year-over-year, with the annual reading at $23.5 million for FY2025, 146.56% up from the prior year.
  • EBIT for Q4 2025 was -$8.6 million at Akebia Therapeutics, down from $4.4 million in the prior quarter.
  • The five-year high for EBIT was $34.1 million in Q2 2022, with the low at -$79.3 million in Q2 2021.
  • Average EBIT over 5 years is -$20.9 million, with a median of -$12.8 million recorded in 2023.
  • The sharpest move saw EBIT tumbled 1141.27% in 2024, then surged 261.48% in 2025.
  • Over 5 years, EBIT stood at -$65.3 million in 2021, then skyrocketed by 92.55% to -$4.9 million in 2022, then surged by 128.22% to $1.4 million in 2023, then crashed by 1141.27% to -$14.3 million in 2024, then surged by 40.22% to -$8.6 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$8.6 million, $4.4 million, and $14.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.